Drug intelligence / Profile preview

IT001

Development stage: Preclinical
Lead developer: Guangdong Celconta Biotechnology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

IT001 is a preclinical-stage allogeneic cell therapy candidate being developed by Guangdong Celconta Biotechnology (XKDBio). It is the lead asset from the company's CAR-iT platform, which utilizes chimeric antigen receptor (CAR) engineered T cells derived from induced pluripotent stem cells (iPSCs). This approach aims to overcome the limitations of autologous CAR-T therapies by providing a standardized, off-the-shelf product with high scalability. While the specific antigen target for IT001 has not been disclosed, the program is intended for the treatment of hematological or solid malignancies.

Beyond the preview

Go deeper on IT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IT001.

Explore the full profile